论文部分内容阅读
为探讨乳腺癌P62Cmyc蛋白表达与雌激素和孕激素受体的关系及其临床意义,采用LSAB免疫组化法对107例乳腺癌标本进行P62Cmyc蛋白检测。结果:P62Cmyc蛋白表达阳性率为63.55%(68/107),在生存时间≤5年、>5年<10年及≥10年者,其P62Cmyc蛋白表达阳性率分别为94.00%(47/50),65.00%(13/20)和21.62%(8/37),表明P62Cmyc蛋白过度表达与乳腺癌的临床分期晚、组织学分级高及腋淋巴结转移有关,而与雌、孕激素受体状况关系不大。由此提示:P62Cmyc蛋白表达可作为判断乳腺癌预后的一个重要指标。
To explore the relationship between the expression of P62Cmyc protein and estrogen and progesterone receptors in breast cancer, LSAB immunohistochemistry was used to detect P62Cmyc protein in 107 breast cancer specimens. RESULTS: The positive rate of P62Cmyc protein expression was 63.55% (68/107). The positive rate of P62Cmyc protein expression in the patients with survival time ≤5 years, >5 years<10 years and ≥10 years was 94 respectively. .00% (47/50), 65.00% (13/20), and 21.62% (8/37), indicating that P62Cmyc overexpression is associated with late clinical staging, high histological grade, and delirium Lymph node metastasis is related to the status of estrogen and progesterone receptors. This suggests that the expression of P62Cmyc protein can be used as an important indicator to determine the prognosis of breast cancer.